脂蛋白(a)在代谢功能障碍相关脂肪性肝病全谱系中的作用:来自组织学与遗传学特征队列的证据
本研究通过多中心横断面肝活检研究(n=332)和英国生物银行前瞻性研究(n=270,004,中位随访12.47年)分析脂蛋白(a)与MASLD全谱系的关系。横断面分析显示脂蛋白(a)每增加1个标准差与高危代谢功能障碍相关脂肪性肝炎呈负相关(OR 0.64,95%CI 0.42-0.97),但前瞻性分析显示脂蛋白(a)低于10.75 nmol/L者肝硬化(HR 1.49,95%CI 1.22-1.81)和肝细胞癌(HR 1.69,95%CI 1.12-2.56)风险高于10.75-21.5 nmol/L者,遗传风险评分呈L型关联。作者认为横断面负相关源于反向因果,遗传预测的极低脂蛋白(a)水平与肝脏健康受损相关。
要点
- 横断面分析中脂蛋白(a)每升高1-SD与高危MASH呈负相关(OR 0.64,95%CI 0.42-0.97)。
- 前瞻性分析中脂蛋白(a)<10.75 nmol/L者肝硬化(HR 1.49)和HCC(HR 1.69)风险高于10.75-21.5 nmol/L者。
- 遗传风险评分与肝脏结局呈L型关联,极低脂蛋白(a)水平与肝脏健康受损相关。
核心结论
- 横断面观察到的脂蛋白(a)与MASLD负相关应归因于反向因果,即肝病存在可能降低脂蛋白(a)水平。
- 遗传预测的极低脂蛋白(a)水平也与前瞻性肝脏健康受损相关。
- 作者认为评估降脂蛋白(a)药物的临床试验应仔细监测达到极低浓度受试者的肝脏不良反应。
研究设计与样本
- 研究1为多中心、横断面、基于肝活检的研究(n=332)。
- 研究2为英国生物银行前瞻性研究(n=270,004,中位随访12.47年)。
- 分析A研究脂蛋白(a)质量与MASLD分期的横断面关联;分析B研究脂蛋白(a)浓度与MASLD、肝硬化和肝细胞癌的前瞻性关联;分析C使用LPA遗传风险评分进行前瞻性分析。
主要发现
- 研究1中脂蛋白(a)每增加1个标准差与高危代谢功能障碍相关脂肪性肝炎呈负相关(OR 0.64,95%CI 0.42-0.97)。
- 研究2中脂蛋白(a)<10.75 nmol/L者较10.75-21.5 nmol/L者肝硬化风险更高(HR 1.49,95%CI 1.22-1.81)。
- 研究2中脂蛋白(a)<10.75 nmol/L者较10.75-21.5 nmol/L者肝细胞癌风险更高(HR 1.69,95%CI 1.12-2.56)。
- 高于10.75-21.5 nmol/L范围时,风险显著正向增加。
- 遗传分析显示LPA遗传风险评分与结局呈L型关联。
临床怎么用
- 作者认为评估降脂蛋白(a)药物的临床试验应仔细监测达到极低浓度受试者的肝脏不良反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lipoprotein(a) (Lp(a)) is an emerging biomarker for cardiometabolic factors. We studied the role of Lp(a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: Three independent analyses were implemented using a multi-center, cross-sectional, liver biopsy-based study (n = 332) (Study 1) and the UK Biobank prospective study (n = 270,004) (Study 2; median follow-up, 12.47 years). In Study 1, we studied the cross-sectional association between Lp(a) mass and MASLD stages (Analysis A). In Study 2, we studied the prospective association between Lp(a) concentration and MASLD, liver cirrhosis, and hepatocellular carcinoma (Analysis B). Finally, these analyses were accompanied by a prospective analysis using LPA Genetic Risk Score (Analysis C). RESULTS: In Study 1, an inverse association between Lp(a) and at-risk metabolic dysfunction-associated steatohepatitis (odds ratioper 1-SD increase, 0.64; 95% confidence interval [CI], 0.42-0.97) was observed. In contrast, when similar associations were examined prospectively (Study 2), subjects with Lp(a) <10.75 nmol/L had a higher risk for cirrhosis (hazard ratio, 1.49; 95% CI, 1.22-1.81) and HCC (hazard ratio, 1.69; 95% CI, 1.12-2.56) compared with subjects with Lp(a) within the 10.75 to 21.5 nmol/L range. Above these levels, the risk increased significantly and positively. Similarly, genetic analysis showed an L-shaped association with LPA Genetic Risk Score. CONCLUSIONS: The inverse association observed in cross-sectional studies should be attributed to reverse causality (ie, the presence of liver disease may decrease Lp(a) levels). Genetically predicted very low Lp(a) levels are also associated with impaired liver health prospectively. Clinical trials evaluating Lp(a)-lowering agents should thus be monitored carefully for adverse liver effects in subjects attaining extremely low concentrations.
引用
- Fan H, Kouvari M, Mingrone G, et al. Lipoprotein (a) in the Full Spectrum of Metabolic Dysfunction-associated Steatotic Liver Disease: Evidence From Histologically and Genetically Characterized Cohorts. Clin Gastroenterol Hepatol. 2024. PMID: 39672249. doi:10.1016/j.cgh.2024.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。